Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)

Gan to kagaku ryoho. Cancer & chemotherapy

Volumn 25, Issue 7, 1998, Pages 1045-1063

  Nomura, Y ^a   Nakajima, M ^a   Tominaga, T ^a   Abe, O ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTROGEN RECEPTOR; MIPROXIFENE PHOSPHATE; TAMOXIFEN;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0032085894     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)